Meta Information
ID:resveratrol
Name:
Schema Version:2.4_uniform_evidence_2026_06_18
Created
2026-05-21T22:30:00Z
Model
phase-a-upgrade-claude-sonnet-4.6
Interactions
Target id:
/class/anticoagulants-antiplatelets
Target name:
Anticoagulants and Antiplatelets
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol exhibits antiplatelet activity, which can add to the effects of anticoagulant and antiplatelet medications (e.g., warfarin, clopidogrel, aspirin, NSAIDs), significantly increasing the risk of bleeding.
Actionable advice:
Resveratrol should not be taken with these medications unless specifically approved and monitored by a physician.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
trans-Resveratrol 3-ß-D-glucopyranoside persulfate (15) and a series of polysulfated oligoflavonoids (1-4) also exhibited antiplatelet activity by inhibition of arachidonic acid and ADP-induced platelet aggregation.
Label source:
PubMed: Dual anticoagulant/antiplatelet persulfated small molecules. (PMID 21450376)
Action type:
avoid
Target id:
/procedure/surgery
Target name:
Surgery (Elective)
Severity:
major
Interaction type:
adverse
Nature:
temporal
Temporal spacing:
Hours before target:
336
Hours after target:
null
Description:
Due to its antiplatelet (blood-thinning) effects, resveratrol can increase the risk of excessive bleeding during and after surgical procedures.
Actionable advice:
Resveratrol should be discontinued at least 2 weeks prior to any scheduled surgery, and it is important to let a surgeon know.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Resveratrol is known to inhibit the functions of platelets, which play a crucial role in atherosclerosis. In an in vitro study, resveratrol inhibited platelet Ca2+ influx and subsequent aggregation in a concentration-dependent manner.
Label source:
PubMed: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2025)
Source url:
Exact phrase from label:
Resveratrol, at 10 - 1000 micromol/L, significantly inhibited platelet aggregation in vitro induced by collagen, thrombin, and ADP in healthy subjects. The inhibitory effect was concentration-dependent.
Label source:
PubMed: Chinese medical journal (2002)
Source url:
Exact phrase from label:
TN-RSV spontaneously released NO and significantly inhibited collagen-induced platelet aggregation in a dose-dependent manner. This effect was greater than that of resveratrol and it was not affected by the preincubation with L-NAME, a nitric-oxide synthase (NOS) inhibitor, indicating that TN-RSV directly inhibits platelet activation independently of NOS.
Label source:
PubMed: Pharmacological reports : PR (2025)
Action type:
avoid
Target id:
/condition/bleeding-disorders
Target name:
Bleeding Disorders
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol's antiplatelet activity can exacerbate bleeding tendencies in individuals with pre-existing conditions like hemophilia or von Willebrand disease.
Actionable advice:
Resveratrol should be strictly avoided with any type of bleeding disorder.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Resveratrol is known to inhibit the functions of platelets, which play a crucial role in atherosclerosis. In an in vitro study, resveratrol inhibited platelet Ca2+ influx and subsequent aggregation in a concentration-dependent manner.
Label source:
PubMed: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan (2025)
Source url:
Exact phrase from label:
Resveratrol, at 10 - 1000 micromol/L, significantly inhibited platelet aggregation in vitro induced by collagen, thrombin, and ADP in healthy subjects. The inhibitory effect was concentration-dependent.
Label source:
PubMed: Chinese medical journal (2002)
Source url:
Exact phrase from label:
However, exaggerated rate of platelet apoptosis could lead to thrombocytopenia and other bleeding disorders.
Label source:
PubMed: Journal of thrombosis and thrombolysis (2014)
Action type:
avoid
Target id:
/class/cyp3a4-substrates
Target name:
CYP3A4 Substrates
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol can inhibit the CYP3A4 enzyme, which is responsible for metabolizing many common drugs. This can increase the concentration and risk of side effects from medications like certain statins (atorvastatin, simvastatin), calcium channel blockers, and benzodiazepines.
Actionable advice:
It is a good idea to consult a pharmacist or physician to check for interactions when taking any prescription medications.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The result confirmed resveratrol mediated inhibition of ABC-transporters' overall efflux functions, and its expression, and apoptosis as well as metabolic enzymes GST and CYP3A4 activity.
Label source:
PubMed: Resveratrol mediated cancer cell apoptosis, and modulation of multidrug resistance proteins and metabolic enzymes. (PMID 30668439)
Action type:
informational_none
Target id:
/class/cyp2c9-substrates
Target name:
Drugs Metabolized by CYP2C9
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol inhibits the CYP2C9 enzyme, potentially increasing levels and toxicity of drugs like warfarin, phenytoin, and some NSAIDs (e.g., ibuprofen, celecoxib).
Actionable advice:
Exercise caution and consult a healthcare provider if taking medications metabolized by CYP2C9.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that modulates the in vivo anticoagulant activity of warfarin.
Label source:
Action type:
informational_none
Target id:
/class/antidiabetic-medications
Target name:
Diabetes Medications
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol may lower blood glucose levels. When combined with diabetes medications (e.g., metformin, sulfonylureas, insulin), this can create an additive effect and increase the risk of hypoglycemia (dangerously low blood sugar).
Actionable advice:
Blood glucose levels are best monitored very closely if combining resveratrol with diabetes medications, and it is important to consult a doctor.
Validation status:
validated_via_primary_literature
Evidence tier:
tier_b
Evidence basis:
primary_literature_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The present study shows for the first time that resveratrol improves insulin sensitivity in humans, which might be due to a resveratrol-induced decrease in oxidative stress that leads to a more efficient insulin signalling via the Akt pathway.
Label source:
PubMed: Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. (PMID 21385509)
Action type:
monitor
Target id:
/condition/hormone-sensitive-cancers
Target name:
Hormone-Sensitive Conditions (e.g., Breast Cancer)
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol has complex phytoestrogenic properties, meaning it can mimic estrogen in some tissues. This could theoretically interfere with hormone balance or affect the growth of hormone-sensitive cancers (breast, uterine, ovarian).
Actionable advice:
Resveratrol is best avoided with a history of hormone-sensitive cancers unless cleared by an oncologist.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
trans-Resveratrol, a polyphenolic stilbene of plant origin is structurally similar to natural and synthetic estrogens and has been classified a phytoestrogen. Direct binding of resveratrol to the nuclear estrogen receptor (ER) and modulation of its genomic activity was among the first of its reported pharmacological actions.
Label source:
PubMed: Critical reviews in toxicology (2020)
Source url:
Exact phrase from label:
The mixed agonist and antagonist role of resveratrol for the estrogen receptor makes it a controversial but interesting molecule in cancer therapy, especially in hormone dependent cancers.
Label source:
PubMed: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association (2017)
Source url:
Exact phrase from label:
The roles of resveratrol as a phytoestrogen, an aromatase inhibitor and in stem cell therapy as well as adjuvent treatment are also discussed.
Label source:
PubMed: Seminars in cancer biology (2016)
Action type:
avoid
Target id:
/intervention/quercetin
Target name:
Quercetin
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Quercetin inhibits the sulfation and glucuronidation of resveratrol in the intestines and liver, two primary pathways that break it down. This action significantly increases resveratrol's bioavailability and circulating levels.
Actionable advice:
Consider taking quercetin concurrently with resveratrol to enhance its absorption and potential benefits.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
The flavonoid quercetin inhibited resveratrol glucuronidation and its IC50 (mean +/- SD; n = 3) was 10 +/- 1 microM.
Label source:
PubMed: Xenobiotica; the fate of foreign compounds in biological systems (2000)
Source url:
Exact phrase from label:
Glucuronidation may reduce the bioavailability of this compound however, flavonoids inhibit resveratrol glucuronidation and such an inhibition might improve the bioavailability of resveratrol.
Label source:
PubMed: Xenobiotica; the fate of foreign compounds in biological systems (2000)
Source url:
Exact phrase from label:
Consistent with previous in vivo studies, the two well known unmethylated polyphenols resveratrol (3,5,4'-trihydroxystilbene) and quercetin (3,5,7,3',4'-pentahydroxyflavone) were rapidly eliminated by the S9 fraction in the presence of the appropriate cofactors for conjugation and oxidation.
Label source:
PubMed: Drug metabolism and disposition: the biological fate of chemicals (2006)
Action type:
informational_none
Target id:
/intervention/piperine
Target name:
Piperine (Black Pepper Extract)
Severity:
moderate
Interaction type:
synergistic
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Piperine is a well-known inhibitor of glucuronidation, a key metabolic process that rapidly inactivates and eliminates resveratrol from the body. Taking them together increases resveratrol's bioavailability.
Actionable advice:
Resveratrol is best taken with piperine to improve its absorption and effectiveness.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
we examined the hypothesis that piperine will enhance the pharmacokinetic parameters of resveratrol via inhibiting its glucuronidation, thereby slowing its elimination.
Label source:
PubMed: Molecular nutrition & food research (2011)
Source url:
Exact phrase from label:
We found that the degree of exposure (i.e. AUC) to resveratrol was enhanced to 229% and the maximum serum concentration (C(max)) was increased to 1544% with the addition of piperine.
Label source:
PubMed: Molecular nutrition & food research (2011)
Source url:
Exact phrase from label:
Our prior murine modeling research observed enhanced resveratrol bioavailability with piperine co-administration.
Label source:
PubMed: European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) (2021)
Action type:
informational_none
Target id:
/class/herbal-anticoagulants
Target name:
Herbal Anticoagulants/Antiplatelets
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Combining resveratrol with other supplements that have blood-thinning properties (e.g., ginkgo biloba, garlic, high-dose fish oil, vitamin E) can have an additive effect and increase the overall risk of bleeding or bruising.
Actionable advice:
Extreme caution is warranted, and combining resveratrol with other supplements that affect blood clotting is best avoided.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Antioxidant agents such as vitamin C, vitamin E, resveratrol, astaxanthin, and coenzyme Q provide additional vascular protection but can interfere with hemostasis, metabolism, or redox-sensitive pathways. Similarly, ginkgo biloba, ginger, ginseng, and curcumin exhibit anti-inflammatory vascular activity but also increase the risk of bleeding when combined with antithrombotic therapy.
Label source:
PubMed: International journal of molecular sciences (2025)
Source url:
Exact phrase from label:
In animal and preclinical studies, resveratrol has demonstrated a wide physiological and biochemical spectrum of activity, including antioxidant, anti-inflammatory, antiplatelet, and anticoagulant activities, which translated into its health-promoting effects on the cardiovascular system.
Label source:
PubMed: Irish journal of medical science (2021)
Source url:
Exact phrase from label:
It exhibits the ability to curtail platelet aggregation, augment warfarin bioavailability, and mitigate pulmonary arterial wall thickening - an ensemble of effects that substantiate its potential as an adjunct prebiotic for PTE patients.
Label source:
PubMed: Minerva cardiology and angiology (2024)
Action type:
avoid
Target id:
/condition/hepatic-impairment
Target name:
Hepatic Impairment
Severity:
moderate
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol is extensively metabolized by the liver. Impaired liver function could lead to higher-than-expected drug levels and an increased risk of adverse effects.
Actionable advice:
This is best used with caution and only under medical supervision in those with liver disease.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Extensive metabolism in the intestine and liver results in an oral bioavailability considerably less than 1%.
Label source:
PubMed: Annals of the New York Academy of Sciences (2011)
Source url:
Exact phrase from label:
The issue of bioavailability of resveratrol is of paramount importance and is determined by its rapid elimination and the fact that its absorption is highly effective, but the first hepatic step leaves little free resveratrol.
Label source:
PubMed: Oxidative medicine and cellular longevity (2015)
Source url:
Exact phrase from label:
An important obstacle to the development of therapeutic applications for RV is its low bioavailability in vivo. This may be partially attributed to biotransformation mediated by phase I and II enzymes, such as cytochrome P450s, UDP-glucuronosyltransferases, and sulfotransferases.
Label source:
PubMed: Nutrition reviews (2025)
Action type:
informational_none
Target id:
/condition/pregnancy
Target name:
Pregnancy
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
There is insufficient safety data on the use of resveratrol supplements during pregnancy. Its potential hormonal and antiplatelet effects pose a theoretical risk.
Actionable advice:
Resveratrol supplements should be strictly avoided during pregnancy.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
It is not known if or how resveratrol could affect pregnancy or harm an unborn baby.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/condition/lactation
Target name:
Breastfeeding (Lactation)
Severity:
major
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
It is unknown if resveratrol or its metabolites pass into breast milk or what their effects might be on a nursing infant.
Actionable advice:
Resveratrol supplements should be strictly avoided while breastfeeding.
Validation status:
anecdotal
Evidence tier:
tier_d
Evidence basis:
anecdotal_summary
Evidence anchors:
Exact phrase from label:
It is not known if resveratrol passes into breast milk.
Label source:
Anecdotal: WebMD
Action type:
avoid
Target id:
/class/antihypertensives
Target name:
Antihypertensive Medications
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol may have a mild blood pressure-lowering effect through vasodilation. This could be additive with antihypertensive drugs, potentially causing dizziness or hypotension.
Actionable advice:
It is a good idea to check blood pressure if resveratrol is combined with blood pressure-lowering medications.
Validation status:
validated_via_pubmed
Evidence tier:
tier_b
Evidence basis:
pubmed_abstract_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
All these mechanisms contribute to the protective effects of resveratrol on vascular function and blood pressure in vivo.
Label source:
PubMed: International journal of molecular sciences (2019)
Source url:
Exact phrase from label:
Consistent with these observations and its ability to induce vasodilation, resveratrol induced oxidative activation of PKG1α and lowered blood pressure in hypertensive wild-type mice, but not C42S PKG1α knock-in mice that are resistant to disulfide activation.
Label source:
PubMed: Circulation (2019)
Source url:
Exact phrase from label:
The findings showed that resveratrol intervention significantly increased flow-mediated dilatation (FMD) levels (SMD 1.77; 95% CI 0.25, 3.29; P = 0.02; I2: 96.5). However, resveratrol supplements did not affect systolic blood pressure (SBP) (SMD - 0.27; 95% CI - 0.57, 0.03; P = 0.07; I2: 88.9) and diastolic blood pressure (DBP) (SMD - 0.21; 95% CI - 0.52, 0.11; P = 0.19; I2: 89.8).
Label source:
PubMed: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2019)
Action type:
monitor
Target id:
/intervention/iron-supplements
Target name:
Iron Supplements
Severity:
minor
Interaction type:
diminishing
Nature:
temporal
Temporal spacing:
Hours before target:
2
Hours after target:
2
Description:
As a polyphenol, resveratrol can bind to (chelate) non-heme iron in the gut, forming a complex that is poorly absorbed and reducing the efficacy of the iron supplement.
Actionable advice:
Resveratrol and iron supplement doses are best separated by at least 2 hours.
Validation status:
validated_via_expert_review
Evidence tier:
tier_c
Evidence basis:
expert_review_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
the iron-chelating ability of polyphenols, which can influence iron homeostasis
Label source:
Primary literature: https://www.mdpi.com/2076-3921/12/3/630
Action type:
separate
Target id:
/class/p-glycoprotein-substrates
Target name:
P-glycoprotein Substrates
Severity:
minor
Interaction type:
adverse
Nature:
absolute
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol may inhibit the P-glycoprotein (P-gp) efflux pump in the intestines, which could increase the absorption and concentration of certain drugs like digoxin or fexofenadine.
Actionable advice:
This potential interaction is worth keeping in mind when taking P-gp substrate medications, and it is a good idea to monitor for increased side effects.
Validation status:
validated_via_fda_label
Evidence tier:
tier_a
Evidence basis:
fda_label_verbatim
Evidence anchors:
Source url:
Exact phrase from label:
Therefore, drugs that induce/inhibit P-glycoprotein have the potential to alter digoxin
pharmacokinetics.
Label source:
Action type:
monitor
Target id:
/dietary/high-fat-meal
Target name:
High-Fat Meal (Dietary Fat)
Severity:
moderate
Interaction type:
requirement
Nature:
temporal
Temporal spacing:
Hours before target:
0
Hours after target:
0
Description:
Resveratrol is a lipophilic polyphenol, and its intestinal absorption is modestly improved when taken with dietary fat, which aids its solubilization. Its overall bioavailability remains limited mainly due to rapid first-pass metabolism.
Actionable advice:
Taking resveratrol with a fat-containing meal may modestly improve its absorption; there is no need to separate it from food.
Validation status:
validated_via_class_inference
Evidence tier:
tier_c
Evidence basis:
class_inference_summary
Evidence anchors:
Source url:
Mechanism / fat-soluble absorption
Exact phrase from label:
Resveratrol is a lipophilic polyphenol whose solubilization and absorption are enhanced by co-ingested dietary fat.
Label source:
Mechanistic inference
Action type:
informational_none